Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats

Tomonori Tateishi, Minoru Watanabe, Hironori Nakura, Masami Tanaka, Toshio Kumai, Shigeko Fujimoto Sakata, Nanaya Tamaki, Kenichiro Ogura, Takahito Nishiyama, Tadashi Watabe, Shinichi Kobayashi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hepatic metabolism is the main determinant in the pharmacokinetics of 5- fluorouracil (5-FU). Its disposition might be affected with liver dysfunction. In the present study, the influence of liver damage induced by bile duct ligation on dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme in 5-FU catabolism, CYP2B, and 5-FU pharmacokinetics were compared in male Sprague-Dawley rats. After 3 weeks of the ligation in two different groups of animals for in vitro and pharmacokinetic experiments, significant increases in serum bilirubin level and spleen weight were found in both groups. No significant differences were noted in bilirubin level or spleen weight of the bile duct ligation group between the two experiment groups. In the in vitro experiment, DPD activity and protein levels determined by Western blot analysis in the bile duct ligation group were slightly but significantly greater than those of a sham-operated group, whereas CYP2B activity and protein level were significantly reduced. These findings were supported by mRNA levels of CYP2B and DPD. When 40 mg/kg 5-FU was administered i.v. in the pharmacokinetic experiment, no significant differences in pharmacokinetic parameters were found between the bile duct ligation and sham-operated groups. These results suggested that DPD activity and protein level were maintained and that 5-FU pharmacokinetics was not altered in the presence of liver damage accompanied by a significant reduction in CYP2B activity and protein level, supporting previous clinical studies showing that mild to moderate liver dysfunction does not affect 5-FU disposition.

Original languageEnglish
Pages (from-to)651-654
Number of pages4
JournalDrug Metabolism and Disposition
Volume27
Issue number6
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Dihydrouracil Dehydrogenase (NADP)
Pharmacokinetics
Bile Ducts
Fluorouracil
Liver
Ducts
Ligation
Rats
Bilirubin
Liver Diseases
Proteins
Spleen
Experiments
Weights and Measures
Metabolism
Sprague Dawley Rats
Animals
Western Blotting
Messenger RNA
Enzymes

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats. / Tateishi, Tomonori; Watanabe, Minoru; Nakura, Hironori; Tanaka, Masami; Kumai, Toshio; Sakata, Shigeko Fujimoto; Tamaki, Nanaya; Ogura, Kenichiro; Nishiyama, Takahito; Watabe, Tadashi; Kobayashi, Shinichi.

In: Drug Metabolism and Disposition, Vol. 27, No. 6, 1999, p. 651-654.

Research output: Contribution to journalArticle

Tateishi, T, Watanabe, M, Nakura, H, Tanaka, M, Kumai, T, Sakata, SF, Tamaki, N, Ogura, K, Nishiyama, T, Watabe, T & Kobayashi, S 1999, 'Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats', Drug Metabolism and Disposition, vol. 27, no. 6, pp. 651-654.
Tateishi, Tomonori ; Watanabe, Minoru ; Nakura, Hironori ; Tanaka, Masami ; Kumai, Toshio ; Sakata, Shigeko Fujimoto ; Tamaki, Nanaya ; Ogura, Kenichiro ; Nishiyama, Takahito ; Watabe, Tadashi ; Kobayashi, Shinichi. / Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats. In: Drug Metabolism and Disposition. 1999 ; Vol. 27, No. 6. pp. 651-654.
@article{0cf7f08e51bd4e2f89cffa412661dd7a,
title = "Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats",
abstract = "Hepatic metabolism is the main determinant in the pharmacokinetics of 5- fluorouracil (5-FU). Its disposition might be affected with liver dysfunction. In the present study, the influence of liver damage induced by bile duct ligation on dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme in 5-FU catabolism, CYP2B, and 5-FU pharmacokinetics were compared in male Sprague-Dawley rats. After 3 weeks of the ligation in two different groups of animals for in vitro and pharmacokinetic experiments, significant increases in serum bilirubin level and spleen weight were found in both groups. No significant differences were noted in bilirubin level or spleen weight of the bile duct ligation group between the two experiment groups. In the in vitro experiment, DPD activity and protein levels determined by Western blot analysis in the bile duct ligation group were slightly but significantly greater than those of a sham-operated group, whereas CYP2B activity and protein level were significantly reduced. These findings were supported by mRNA levels of CYP2B and DPD. When 40 mg/kg 5-FU was administered i.v. in the pharmacokinetic experiment, no significant differences in pharmacokinetic parameters were found between the bile duct ligation and sham-operated groups. These results suggested that DPD activity and protein level were maintained and that 5-FU pharmacokinetics was not altered in the presence of liver damage accompanied by a significant reduction in CYP2B activity and protein level, supporting previous clinical studies showing that mild to moderate liver dysfunction does not affect 5-FU disposition.",
author = "Tomonori Tateishi and Minoru Watanabe and Hironori Nakura and Masami Tanaka and Toshio Kumai and Sakata, {Shigeko Fujimoto} and Nanaya Tamaki and Kenichiro Ogura and Takahito Nishiyama and Tadashi Watabe and Shinichi Kobayashi",
year = "1999",
language = "English",
volume = "27",
pages = "651--654",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats

AU - Tateishi, Tomonori

AU - Watanabe, Minoru

AU - Nakura, Hironori

AU - Tanaka, Masami

AU - Kumai, Toshio

AU - Sakata, Shigeko Fujimoto

AU - Tamaki, Nanaya

AU - Ogura, Kenichiro

AU - Nishiyama, Takahito

AU - Watabe, Tadashi

AU - Kobayashi, Shinichi

PY - 1999

Y1 - 1999

N2 - Hepatic metabolism is the main determinant in the pharmacokinetics of 5- fluorouracil (5-FU). Its disposition might be affected with liver dysfunction. In the present study, the influence of liver damage induced by bile duct ligation on dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme in 5-FU catabolism, CYP2B, and 5-FU pharmacokinetics were compared in male Sprague-Dawley rats. After 3 weeks of the ligation in two different groups of animals for in vitro and pharmacokinetic experiments, significant increases in serum bilirubin level and spleen weight were found in both groups. No significant differences were noted in bilirubin level or spleen weight of the bile duct ligation group between the two experiment groups. In the in vitro experiment, DPD activity and protein levels determined by Western blot analysis in the bile duct ligation group were slightly but significantly greater than those of a sham-operated group, whereas CYP2B activity and protein level were significantly reduced. These findings were supported by mRNA levels of CYP2B and DPD. When 40 mg/kg 5-FU was administered i.v. in the pharmacokinetic experiment, no significant differences in pharmacokinetic parameters were found between the bile duct ligation and sham-operated groups. These results suggested that DPD activity and protein level were maintained and that 5-FU pharmacokinetics was not altered in the presence of liver damage accompanied by a significant reduction in CYP2B activity and protein level, supporting previous clinical studies showing that mild to moderate liver dysfunction does not affect 5-FU disposition.

AB - Hepatic metabolism is the main determinant in the pharmacokinetics of 5- fluorouracil (5-FU). Its disposition might be affected with liver dysfunction. In the present study, the influence of liver damage induced by bile duct ligation on dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme in 5-FU catabolism, CYP2B, and 5-FU pharmacokinetics were compared in male Sprague-Dawley rats. After 3 weeks of the ligation in two different groups of animals for in vitro and pharmacokinetic experiments, significant increases in serum bilirubin level and spleen weight were found in both groups. No significant differences were noted in bilirubin level or spleen weight of the bile duct ligation group between the two experiment groups. In the in vitro experiment, DPD activity and protein levels determined by Western blot analysis in the bile duct ligation group were slightly but significantly greater than those of a sham-operated group, whereas CYP2B activity and protein level were significantly reduced. These findings were supported by mRNA levels of CYP2B and DPD. When 40 mg/kg 5-FU was administered i.v. in the pharmacokinetic experiment, no significant differences in pharmacokinetic parameters were found between the bile duct ligation and sham-operated groups. These results suggested that DPD activity and protein level were maintained and that 5-FU pharmacokinetics was not altered in the presence of liver damage accompanied by a significant reduction in CYP2B activity and protein level, supporting previous clinical studies showing that mild to moderate liver dysfunction does not affect 5-FU disposition.

UR - http://www.scopus.com/inward/record.url?scp=0033054515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033054515&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 651

EP - 654

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 6

ER -